サルコイドーシス治療薬の世界市場レポート 2025年

サルコイドーシス治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.1％で104億7,000万米ドルに成長します。予測期間の成長は、サルコイドーシスの有病率の上昇、希少疾患や自己免疫疾患に対する認知度の向上、早期発見を可能にする診断技術の進歩、ヘルスケア支出の増加、専門治療や生物学的治療への患者アクセスの改善などに起因すると考えられます。予測期間中に予想される主な動向としては、免疫療法技術の進歩、創薬における人工知能の利用、画像診断の技術的改善、革新的なドラッグデリバリーシステムの開発、デジタルヘルスツールの導入などが挙げられます。

臨床試験の増加は、サルコイドーシス治療薬市場の成長を促進すると予想されます。臨床試験は、医療治療や介入の安全性、有効性、副作用を評価するためにヒトを対象に実施される調査研究です。このような臨床試験の増加は、徹底的な安全性と有効性の試験を必要とする個別化された革新的な治療に対する需要の高まりに後押しされています。サルコイドーシス治療薬は、患者の転帰を改善し、より効果的な治療法を特定するための性能を評価するために、これらの臨床試験で使用されています。例えば、ロンドンに本部を置く業界団体である英国製薬工業協会は2023年11月、英国における業界臨床試験の年間募集人数が15％増加し、参加者数が2021-22年の3万6,722人から2022-23年には4万2,088人に増加すると報告しました。その結果、臨床試験数の拡大がサルコイドーシス治療薬市場の成長に寄与しています。

サルコイドーシス治療薬市場の主要企業は、抗TNFaモノクローナル抗体などの革新的な治療薬の開発に注力し、治療抵抗性の症例に対処して疾患管理の成果を高めています。これらの生物学的製剤は、腫瘍壊死因子α（TNFa）を阻害することにより、サルコイドーシスや他の自己免疫疾患などの炎症と組織障害を軽減します。2023年11月、米国の製薬会社ゼントリア社は、サルコイドーシスの治療薬XTMAB-16について、欧州医薬品庁（EMA）から希少疾病用医薬品の指定を受けた。XTMAB-16は、サルコイドーシスに特徴的な肉芽腫形成に関与する重要な炎症分子であるTNFaを標的とするヒト・ミュアのキメラモノクローナル抗体です。この薬剤は炎症プロセスを阻害し、特に肺に影響を及ぼす肺サルコイドーシスにおいて肉芽腫の発生を遅らせる可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界サルコイドーシス治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のサルコイドーシス治療薬市場：成長率分析
• 世界のサルコイドーシス治療薬市場の実績：規模と成長, 2019-2024
• 世界のサルコイドーシス治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界サルコイドーシス治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のサルコイドーシス治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 眼サルコイドーシス
• 神経サルコイドーシス
• 心臓サルコイドーシス
• 筋骨格サルコイドーシス
• 皮膚サルコイドーシス
• 腎サルコイドーシス
• 肝サルコイドーシス
• 脾臓および骨髄のサルコイドーシス
• 肺サルコイドーシス
• 世界のサルコイドーシス治療薬市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫抑制剤
• 抗マラリア薬
• 腫瘍壊死因子α（TNF-α）阻害剤
• 世界のサルコイドーシス治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺病変
• 皮膚の病変
• 心臓病変
• 神経学的関与
• 世界のサルコイドーシス治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• トピック
• 世界のサルコイドーシス治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外科センター
• 診断センター
• その他のエンドユーザー
• 世界のサルコイドーシス治療薬市場眼サルコイドーシスの分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前部ぶどう膜炎
• 後部ぶどう膜炎
• ぶどう膜炎
• 結膜サルコイドーシス
• 世界のサルコイドーシス治療薬市場神経サルコイドーシスの分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 脳神経障害
• 髄膜障害
• 脊髄サルコイドーシス
• 末梢神経障害
• 世界のサルコイドーシス治療薬市場心臓サルコイドーシスの病型別分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不整脈
• 心臓ブロック
• 心筋症
• 心不全
• 世界のサルコイドーシス治療薬市場筋骨格系サルコイドーシスの分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節症
• ミオパチー
• 骨病変
• サルコイドーシス
• 世界のサルコイドーシス治療薬市場皮膚サルコイドーシスの病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 狼瘡
• 結節性紅斑
• 斑状丘疹病変
• 瘢痕サルコイドーシス
• 世界のサルコイドーシス治療薬市場腎サルコイドーシスの病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肉芽腫性間質性腎炎
• 腎石灰化症
• 高カルシウム尿症
• 尿細管間質性腎炎
• 世界のサルコイドーシス治療薬市場肝サルコイドーシスの病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肉芽腫性肝炎
• 肝腫大
• 胆汁うっ滞
• 門脈圧亢進症
• 世界のサルコイドーシス治療薬市場脾臓および骨髄サルコイドーシスの病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 脾腫
• 脾機能亢進症
• 骨髄浸潤
• 汎血球減少症
• 世界のサルコイドーシス治療薬市場肺サルコイドーシスの病型別分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 門脈リンパ節腫脹
• 間質性肺疾患
• 線維性サルコイドーシス
• 気管支閉塞

第7章 地域別・国別分析

• 世界のサルコイドーシス治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のサルコイドーシス治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サルコイドーシス治療薬市場：競合情勢
• サルコイドーシス治療薬市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG. Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Hikma Pharmaceuticals PLC
• Lupin Limited
• Mallinckrodt plc
• Kyorin Pharmaceutical Co. Ltd.
• Molecure S.A.
• aTyr Pharma Inc.
• Xentria Inc.
• Relief Therapeutics Holding AG
• Foresee Pharmaceuticals Co. Ltd.
• OrphAI Therapeutics Inc.
• Bellus Health Inc.
• AI Therapeutics Inc.
• Araim Pharmaceuticals Inc.
• Kinevant Sciences GmbH
• SarcoMed USA Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• サルコイドーシス治療薬市場2029：新たな機会を提供する国
• サルコイドーシス治療薬市場2029：新たな機会を提供するセグメント
• サルコイドーシス治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A sarcoidosis drug refers to any pharmacological substance used to manage the abnormal immune activity and granuloma development associated with sarcoidosis-a systemic inflammatory disease that primarily affects the lungs and lymph nodes. These medications work to alleviate symptoms and prevent damage to organs.

The primary types of sarcoidosis drugs are targeted for conditions such as ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, and sarcoidosis of the spleen, bone marrow, and lungs. Ocular sarcoidosis refers specifically to inflammation in the eyes caused by the disease, marked by the formation of granulomas in ocular tissues. This can lead to symptoms like redness, pain, and potential vision loss. Treatment approaches include corticosteroids, immunosuppressants, antimalarial drugs, and tumor necrosis factor-alpha (TNF-alpha) inhibitors. These medications are used to treat organ involvement in the lungs, skin, heart, and nervous system, and they can be administered orally, intravenously, or topically. Key end users include hospitals, clinics, surgical centers, diagnostic centers, and other healthcare institutions.

The sarcoidosis drug market research report is one of a series of new reports from The Business Research Company that provides sarcoidosis drug market statistics, including the sarcoidosis drug industry's global market size, regional shares, competitors with the sarcoidosis drug market share, detailed sarcoidosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis drug market. This sarcoidosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sarcoidosis drug market size has grown strongly in recent years. It will grow from $7.43 billion in 2024 to $7.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be credited to increased investment in orphan drug development, expanded research and development efforts focused on granulomatous diseases, wider use of corticosteroids and immunosuppressants for symptom control, an expanding clinical pipeline of innovative sarcoidosis treatments, and a heightened emphasis on personalized and targeted therapeutic approaches.

The sarcoidosis drug market size is expected to see strong growth in the next few years. It will grow to $10.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to the rising prevalence of sarcoidosis, increased awareness of rare and autoimmune diseases, advancements in diagnostic techniques enabling earlier detection, higher healthcare spending, and improved patient access to specialty treatments and biologic therapies. Key trends expected during the forecast period include progress in immunotherapy technologies, the use of artificial intelligence in drug discovery, technological improvements in diagnostic imaging, the development of innovative drug delivery systems, and the incorporation of digital health tools.

The increasing number of clinical trials is expected to drive the growth of the sarcoidosis drug market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and side effects of medical treatments or interventions. This rise in clinical trials is fueled by the growing demand for personalized and innovative treatments that require thorough safety and efficacy testing. Sarcoidosis drugs are used in these trials to evaluate their performance in improving patient outcomes and identifying more effective therapies. For example, in November 2023, the Association of the British Pharmaceutical Industry, a trade association based in London, reported a 15% increase in annual recruitment for industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. As a result, the expanding number of clinical trials is contributing to the growth of the sarcoidosis drug market.

Major companies in the sarcoidosis drug market are focusing on the development of innovative therapies such as anti-TNFa monoclonal antibodies to address treatment-resistant cases and enhance disease management outcomes. These biologic drugs work by blocking tumor necrosis factor-alpha (TNFa), thereby reducing inflammation and tissue damage in conditions like sarcoidosis and other autoimmune diseases. In November 2023, Xentria Inc., a pharmaceutical company based in the US, received orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16, a treatment for sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody that targets TNFa, a critical inflammatory molecule involved in granuloma formation, which is characteristic of sarcoidosis. The drug is designed to interrupt the inflammatory process and potentially slow granuloma development, especially in pulmonary sarcoidosis, which impacts the lungs.

In June 2023, Xentria Inc. entered into a collaboration with Meitheal Pharmaceuticals Inc. to accelerate the development and commercialization of XTMAB-16. This partnership aims to deliver a targeted and effective treatment for pulmonary sarcoidosis, addressing a significant unmet medical need. Meitheal Pharmaceuticals Inc. is a US-based pharmaceutical manufacturer involved in the production of sarcoidosis drugs.

Major players in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

North America was the largest region in the sarcoidosis drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sarcoidosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sarcoidosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcoidosis drug market consists of sales of hydroxychloroquine, leflunomide, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sarcoidosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sarcoidosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sarcoidosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcoidosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Ocular Sarcoidosis; Neurosarcoidosis; Cardiac Sarcoidosis; Musculoskeletal Sarcoidosis; Cutaneous Sarcoidosis; Renal Sarcoidosis; Hepatic Sarcoidosis; Sarcoidosis Of The Spleen and Bone Marrow; Pulmonary Sarcoidosis
• 2) By Mechanism of Action: Corticosteroid; Immunosuppressants; Antimalarial; Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
• 3) By Indication: Lung Involvement; Skin Involvement; Cardiac Involvement; Neurological Involvement
• 4) By Route of Administration: Oral; Intravenous; Topical
• 5) By End User: Hospitals And Clinics; Surgical Centers; Diagnostic Centers; Other End Users

Subsegments

• 1) By Ocular Sarcoidosis: Anterior uveitis; Posterior uveitis; Panuveitis; Conjunctival sarcoidosis
• 2) By Neurosarcoidosis: Cranial neuropathy; Meningeal involvement; Spinal cord sarcoidosis; Peripheral neuropathy
• 3) By Cardiac Sarcoidosis: Arrhythmias; Heart block; Cardiomyopathy; Heart failure
• 4) By Musculoskeletal Sarcoidosis: Arthropathy; Myopathy; Bone lesions; Sarcoid arthritis
• 5) By Cutaneous Sarcoidosis: Lupus pernio; Erythema nodosum; Maculopapular lesions; Scar sarcoidosis
• 6) By Renal Sarcoidosis: Granulomatous interstitial nephritis; Nephrocalcinosis; Hypercalciuria; Tubulointerstitial nephritis
• 7) By Hepatic Sarcoidosis: Granulomatous hepatitis; Hepatomegaly; Cholestasis; Portal hypertension
• 8) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly; Hypersplenism; Bone marrow infiltration; Pancytopenia

9) By Hilar lymphadenopathy; Interstitial lung disease; Fibrotic sarcoidosis; Bronchial obstruction

• Companies Mentioned: AbbVie Inc.; Novartis AG.; Viatris Inc.; Boehringer Ingelheim International GmbH; Aurobindo Pharma Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sarcoidosis Drug Market Characteristics

3. Sarcoidosis Drug Market Trends And Strategies

4. Sarcoidosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sarcoidosis Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sarcoidosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sarcoidosis Drug Market Growth Rate Analysis
• 5.4. Global Sarcoidosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sarcoidosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sarcoidosis Drug Total Addressable Market (TAM)

6. Sarcoidosis Drug Market Segmentation

• 6.1. Global Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ocular Sarcoidosis
• Neurosarcoidosis
• Cardiac Sarcoidosis
• Musculoskeletal Sarcoidosis
• Cutaneous Sarcoidosis
• Renal Sarcoidosis
• Hepatic Sarcoidosis
• Sarcoidosis of the Spleen and Bone Marrow
• Pulmonary Sarcoidosis
• 6.2. Global Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroid
• Immunosuppressants
• Antimalarial
• Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
• 6.3. Global Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Involvement
• Skin Involvement
• Cardiac Involvement
• Neurological Involvement
• 6.4. Global Sarcoidosis Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Topical
• 6.5. Global Sarcoidosis Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Surgical Centers
• Diagnostic Centers
• Other End Users
• 6.6. Global Sarcoidosis Drug Market, Sub-Segmentation Of Ocular Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anterior uveitis
• Posterior uveitis
• Panuveitis
• Conjunctival sarcoidosis
• 6.7. Global Sarcoidosis Drug Market, Sub-Segmentation Of Neurosarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cranial neuropathy
• Meningeal involvement
• Spinal cord sarcoidosis
• Peripheral neuropathy
• 6.8. Global Sarcoidosis Drug Market, Sub-Segmentation Of Cardiac Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arrhythmias
• Heart block
• Cardiomyopathy
• Heart failure
• 6.9. Global Sarcoidosis Drug Market, Sub-Segmentation Of Musculoskeletal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arthropathy
• Myopathy
• Bone lesions
• Sarcoid arthritis
• 6.10. Global Sarcoidosis Drug Market, Sub-Segmentation Of Cutaneous Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lupus pernio
• Erythema nodosum
• Maculopapular lesions
• Scar sarcoidosis
• 6.11. Global Sarcoidosis Drug Market, Sub-Segmentation Of Renal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatous interstitial nephritis
• Nephrocalcinosis
• Hypercalciuria
• Tubulointerstitial nephritis
• 6.12. Global Sarcoidosis Drug Market, Sub-Segmentation Of Hepatic Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatous hepatitis
• Hepatomegaly
• Cholestasis
• Portal hypertension
• 6.13. Global Sarcoidosis Drug Market, Sub-Segmentation Of Sarcoidosis Of The Spleen And Bone Marrow, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Splenomegaly
• Hypersplenism
• Bone marrow infiltration
• Pancytopenia
• 6.14. Global Sarcoidosis Drug Market, Sub-Segmentation Of Pulmonary Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hilar lymphadenopathy
• Interstitial lung disease
• Fibrotic sarcoidosis
• Bronchial obstruction

7. Sarcoidosis Drug Market Regional And Country Analysis

• 7.1. Global Sarcoidosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sarcoidosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sarcoidosis Drug Market

• 8.1. Asia-Pacific Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sarcoidosis Drug Market

• 9.1. China Sarcoidosis Drug Market Overview
• 9.2. China Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sarcoidosis Drug Market

• 10.1. India Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sarcoidosis Drug Market

• 11.1. Japan Sarcoidosis Drug Market Overview
• 11.2. Japan Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sarcoidosis Drug Market

• 12.1. Australia Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sarcoidosis Drug Market

• 13.1. Indonesia Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sarcoidosis Drug Market

• 14.1. South Korea Sarcoidosis Drug Market Overview
• 14.2. South Korea Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sarcoidosis Drug Market

• 15.1. Western Europe Sarcoidosis Drug Market Overview
• 15.2. Western Europe Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sarcoidosis Drug Market

• 16.1. UK Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sarcoidosis Drug Market

• 17.1. Germany Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sarcoidosis Drug Market

• 18.1. France Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sarcoidosis Drug Market

• 19.1. Italy Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sarcoidosis Drug Market

• 20.1. Spain Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sarcoidosis Drug Market

• 21.1. Eastern Europe Sarcoidosis Drug Market Overview
• 21.2. Eastern Europe Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sarcoidosis Drug Market

• 22.1. Russia Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sarcoidosis Drug Market

• 23.1. North America Sarcoidosis Drug Market Overview
• 23.2. North America Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sarcoidosis Drug Market

• 24.1. USA Sarcoidosis Drug Market Overview
• 24.2. USA Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sarcoidosis Drug Market

• 25.1. Canada Sarcoidosis Drug Market Overview
• 25.2. Canada Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sarcoidosis Drug Market

• 26.1. South America Sarcoidosis Drug Market Overview
• 26.2. South America Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sarcoidosis Drug Market

• 27.1. Brazil Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sarcoidosis Drug Market

• 28.1. Middle East Sarcoidosis Drug Market Overview
• 28.2. Middle East Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sarcoidosis Drug Market

• 29.1. Africa Sarcoidosis Drug Market Overview
• 29.2. Africa Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sarcoidosis Drug Market Competitive Landscape And Company Profiles

• 30.1. Sarcoidosis Drug Market Competitive Landscape
• 30.2. Sarcoidosis Drug Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

31. Sarcoidosis Drug Market Other Major And Innovative Companies

• 31.1. Hikma Pharmaceuticals PLC
• 31.2. Lupin Limited
• 31.3. Mallinckrodt plc
• 31.4. Kyorin Pharmaceutical Co. Ltd.
• 31.5. Molecure S.A.
• 31.6. aTyr Pharma Inc.
• 31.7. Xentria Inc.
• 31.8. Relief Therapeutics Holding AG
• 31.9. Foresee Pharmaceuticals Co. Ltd.
• 31.10. OrphAI Therapeutics Inc.
• 31.11. Bellus Health Inc.
• 31.12. AI Therapeutics Inc.
• 31.13. Araim Pharmaceuticals Inc.
• 31.14. Kinevant Sciences GmbH
• 31.15. SarcoMed USA Inc.

32. Global Sarcoidosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sarcoidosis Drug Market

34. Recent Developments In The Sarcoidosis Drug Market

35. Sarcoidosis Drug Market High Potential Countries, Segments and Strategies

• 35.1 Sarcoidosis Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sarcoidosis Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sarcoidosis Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer